Imaging, CSF, and blood biomarker provide diagnostic means to detect Alzheimer's and related dementia. However, they are utilized after symptoms appear and can be costly and/or invasive. Cognition and olfactory assessments provide a cost effective and non-invasive means to detect impairment comparable to imaging. In addition to the olfactory screen, Aromha utilize a multi-modal approach including imaging and blood biomarkers to obtain a higher fidelity signal.